Orum Therapeutics to Participate in NDR Hosted by Mirae Asset
Orum Therapeutics will participate in a Non-Deal Roadshow (NDR) hosted by Mirae Asset Securities. During this event, the company will hold one-on-one meetings with institutional investors from September 1-3 (KST), introducing the company's proprietary Degrader-Antibody Conjugate (DAC) platform and strategic business initiatives.
Advancing ORM-1153 into the Clinic: Conference Call on IND Clearance & Clinical Study Overview
Orum Therapeutics will hold a conference call to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 clinical study.
Event Details
Date: August 24, 2026
Time: 07:00 AM KST
*The Conference Call has ended. You can watch the video by clicking “View Conference Call Replay” below.
Webcast: View Conference Call Replay
Presentation: View Presentation
Orum to participate in Shinhan Bio Forum in Daejeon
Shinhan Securities is hosting an event inviting institutional investors to its biotech forum in Daejeon. During this event, Orum Therapeutics will hold a CEO investor round-table with institutional investors at the Hotel Interciti on July 9th from 4:10 PM to 5:00 PM KST and introduce the company's proprietary degrader-antibody conjugate (DAC) platform and strategic business initiatives.
Orum to participate in KOSDAQ CONNECT 2026
The KOSDAQ CONNECT event will bring together over 100 KOSDAQ-listed companies, institutional investors, venture capitalists (VCs), and securities firms. Through this event, we plan to provide institutional investors with key updates on Orum’s proprietary Degrader Antibody Conjugate (DAC) platform and strategic business initiatives
Orum to participate in a Hong Kong NDR, co-hosted by HSBC and Mirae Asset Securities
Event Details
Orum Therapeutics will participate in a Non-Deal Roadshow (NDR) in Hong Kong on June 12–15, 2026, co-hosted by HSBC and Mirae Asset Securities. The roadshow offers institutional investors key updates on Orum’s proprietary Degrader Antibody Conjugate (DAC) platform and strategic business initiatives. Executive leadership will host 1-on-1 sessions to discuss pipeline progression and long-term milestones.
Notice of the 10th Annual General Meeting 2026
Webcast Registration
Dear Shareholders,
We would like to express our gratitude for your continued interest and unwavering support. It is thanks to your encouragement that we have been able to take significant steps forward in our challenging mission to develop innovative new medicines.
Our upcoming Annual General Meeting (AGM) is a meaningful opportunity for us to share our achievements over the past year and discuss our vision for a brighter future. We cordially invite you to attend, share your valuable insights, and witness the continued growth of Orum Therapeutics.
📅 Meeting Details (AGM & Webcast Access Info)
Date & Time: March 27, 2026, at 9:00 AM KST
Eligibility: Shareholder as of Dec 31st, 2025
Location: 3/F Conference Hall, Exhibition Center 1, DCC Daejeon Convention Center, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Requirements: Valid photo ID
Webcast Application Period: March 23 9AM KST to March 26 4PM KST
Key Agenda:
Approval of the 10th Term Financial Statements
Appointment of Outside Directors
Online Participation
For shareholders who are unable to attend in person, we have arranged for real-time online participation. Please note that online voting will not be available for those joining via the webcast
Webcast: Register Here (Registration is closed)
Please contact IR for further assistance (ir@orumrx.com)
Important Notice:
· Attendance at the online General Meeting of Shareholders is not recognized as attendance at the General Meeting of Shareholders under the Commercial Act, nor are voting rights or the right to speak granted.
· This live broadcast is provided exclusively to the shareholder and viewing rights cannot be transferred to a third party.
· Screen capturing, recording, filming, reproduction, and external posting or distribution without the Company's consent are prohibited.
J.P. Morgan Healthcare Conference
Event Details
Date: January 12–15, 2026
Location: San Francisco, California, USA
Corporate Day Hosted by Mirae Asset
Event Details
Date & Time: November 25, 2025 , 13:30 pm - 16:30 pm KST
Location: 56 Gukjegeumyung-ro, Yeouido-dong, Seoul
UBS Global Healthcare Conference
Event Details
Date: November 9-12, 2025
Location: Palm Beach, Florida, USA
2025 Extraordinary General Meeting
Event Details
The 2025 Extraordinary General Meeting took place on Friday, Aug 1, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Proposal Reference Material ( KR / EN )
Outcomes : KR / EN
A total of 9,268,387 shares were represented in person or by proxy at the Company's Extraordinary General Meeting of Shareholders: the representation rate was 43.99% based on the total shares outstanding and entitled to vote held by persons other than the Principal Shareholder and its Affiliates
Proposal No. 1 : Election of directors
Proposal 1-1 : Election of Executive Director Lee Sung Joo | Approved
Proposal 1-2 : Election of Non-Executive Director Peter Unnam Park | Approved
Proposal No. 2 : Approval of Capital Reserve Reduction | Approved
Proposal No. 3 : Approval of Stock Option Grant | Approved
Proposal No. 4 : Approval of Amendment to the Articles of Incorporation | Approved
NDR (Non-Deal Roadshow) Hosted by Samsung Securities
Event Details
Title: NDR (Non-Deal Roadshow) Hosted by Samsung Securities
Date and Time: Monday, 2 June 2025 - Wednesday, 4 June 2025
UBS Asian Investment Conference 2025
Event Details
Title: UBS Asian Investment Conference 2025
Date and Time: Thursday, 29 May 2025
Samsung Global Investors Conference 2025
Event Details
Title: Samsung Global Investors Conference 2025
Date and Time: Thursday, 15 May 2025
2025 9th Annual General Meeting
Event Details
The 2025 9th Annual General Meeting took place on Friday, March 28, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Presentation
Proposal Reference Material ( KR / EN )
Annual Report
Outcomes : KR / EN
A total of 12,106,876 shares were represented in person or by proxy at the Company's 9th Annual Meeting of Shareholders: the representation rate was 65.69% based on the total shares outstanding and entitled to vote held by persons other than the Principal Shareholder and its Affiliates
Proposal No. 1 : Approval of the FY2024 Financial Statements | Approved
Proposal No. 2 : Approval of Director Remuneration Limit | Approved
Proposal No. 3 : Approval of Auditor Renumeration Limit | Approved
Proposal No. 4 : Approval of Amendments to the Articles of Incorporation | Approved
2024 Annual Result Conference Call
Event Details
Title: 2024 Annual Result Conference Call
Date and Time: Wednesday, 26 March 2025
Orum Therapeutics to Host Fourth Quarter 2024 Earnings Conference Call
Event Details
Title Orum Therapeutics to Host Fourth Quarter 2024 Earnings Conference Call
Date and Time 3/28/25 9:00 KST, 3/27/25 20:00 EST
UBS Asia Healthcare Corporate Day - Hong Kong 2024
Event Details
Title: UBS Asia Healthcare Corporate Day - Hong Kong 2024
Date and Time: Thursday, 28 - Friday, 29 November 2024
Orum Therapeutics to Hold Analyst Day in Korea
Event Details
Title: Orum Therapeutics to Hold Analyst Day in Korea
Date and Time: 10/18/24, All day
Orum Therapeutics to Host a Global Media Conference Call for the IPO
Event Details
Title: Orum to Host a Global Media Conference Call for the IPO
Date and Time: 10/7/24 10:00 KST, 10/6/24 20:00 EST